What the New Controlled Substances Regulations (SOR/2025-242) Mean for Manufacturers and Dealers

A practical breakdown of Canada's biggest controlled substances reform in decades, now in force as of 1 October 2026, and how to stay compliant.

What Is SOR/2025-242?

SOR/2025-242, formally titled the Controlled Substances Regulations, was registered on 28 November 2025 by Order in Council P.C. 2025-840, and published in the Canada Gazette, Part II, Volume 159, Number 26 on 17 December 2025. It was made by the Governor in Council on the recommendation of the Minister of Health under subsection 55(1) of the Controlled Drugs and Substances Act (CDSA). It came into force on 1 October 2026.

In plain language, the CSR is Health Canada's long-anticipated consolidation of Canada's controlled substances framework into a single, modernized regulation. Before 1 October 2026 the former regulations applied. Since that date, the new framework governs every stage of the controlled substances lifecycle, from dealer licensing and transactional records through prescriptions, hospital handling, government laboratory activities, and personal-use exemptions.

The reform is significant for one practical reason: for the first time in Canadian regulatory history, narcotics, controlled drugs, targeted substances, and restricted drugs are governed by a single, harmonized rulebook. The Schedules to the CSR preserve the traditional substance categories, but the operational requirements, security, reporting, recordkeeping, destruction, import and export, now share one consistent architecture.

Now In Force: What Changed on 1 October 2026

What it is: as of 1 October 2026 the CSR is the operative law for controlled substances in Canada. Why it matters: the compliance obligations below are no longer upcoming, they are current. What to do: confirm each item against your own site now, because the first monthly reporting cycles and the first inspections under the new framework are already here.

Why the Consolidation Happened

Canada regulated controlled substances through a patchwork of instruments for decades. A licensed dealer producing a Schedule I narcotic, a Schedule II controlled drug, and a Schedule IV benzodiazepine at the same site previously navigated several regulations, often with overlapping but inconsistent requirements for security, recordkeeping, and reporting. Health Canada's stated objective was to eliminate that friction, clarify what compliance looks like, reduce administrative duplication, and modernize oversight tools.

For most licence holders the rationale is welcome. The reality, however, is that consolidation does not mean dilution. The CSR introduces stricter reporting cadences, tighter qualification standards for designated persons, and clearer enforcement levers. Companies that operated comfortably under the old regime should not assume their existing systems, SOPs, and personnel structures transfer cleanly into the new framework.

The Big Operational Shift: From Annual to Monthly Reporting

Of every change introduced by SOR/2025-242, this is the one most likely to disrupt day-to-day operations, and it is now live.

Under the former regulations, licensed dealers submitted an annual report on regulated activities, with ample time to reconcile inventory, address gaps, and refine narratives before submission.

Under the CSR, licensed dealers must submit monthly reports on regulated activities. That is a twelvefold increase in submission cadence and, more importantly, a fundamental change in the operational rhythm of compliance.

What this means in practice:

• Inventory reconciliation cycles must compress. A monthly close requires that physical counts, receipts, dispositions, packaging, production, and destruction records all reconcile within days of month-end, not weeks.
• Data infrastructure is critical. Manual spreadsheets that supported annual reporting struggle at monthly cadence. Many dealers need validated ERP, inventory, or compliance software to keep up.
• Personnel capacity must be reviewed. Compliance, quality assurance, and finance functions all see higher workload. Staffing models built around an annual peak need to flatten across the year.
• Reporting governance must tighten. A monthly report submitted in haste, with errors or omissions, creates a record that compounds risk. Each monthly submission is a potential inspection trigger.

Importantly, the CSR clarifies what stays outside the monthly report. Unexplainable losses and thefts are not bundled into monthly submissions. They keep their own urgent timelines:

• Loss of a controlled substance that cannot be explained on the basis of normally accepted business activities: a written report to the Minister within 72 hours of becoming aware.
• Theft: a written report to a police force within 24 hours, and a written report to the Minister within 72 hours.
• Suspicious transactions that may relate to diversion to an illicit market or use: a written report to the Minister within 72 hours.
• Loss or theft of a licence or permit: a written report to the Minister within 72 hours.

The Unified Licensing Structure

The second major shift is structural. SOR/2025-242 replaced the former substance-specific licence regimes with a unified dealer's licence framework.

Who Needs a Dealer's Licence?

A dealer's licence is required for any person who, at a given site, intends to:

• Produce a controlled substance (with limited exemptions for pharmacists or government laboratories);
• Package, sell, provide, deliver, send, or transport a controlled substance (with carve-outs for pharmacists, practitioners, hospitals, the Minister, and certain individuals);
• Import or export a controlled substance (with exemptions for the Minister, government laboratories, and certain individuals); or
• Destroy a controlled substance, where destruction is the only activity intended.

Designated Roles: Senior Person in Charge and Qualified Person in Charge

The CSR formalizes, and harmonizes across all substance categories, the requirement for two designated individuals at every licensed site:

1. Senior Person in Charge (SPIC): one individual with overall responsibility for management of activities involving controlled substances at the site.
2. Qualified Person in Charge (QPIC): one individual who supervises day-to-day activities and is accountable for compliance with the CSR, the licence, and any permits. An Alternate QPIC may also be designated.

The QPIC qualifications are explicit and non-trivial. The individual must work at the site, hold a recognized post-secondary credential in a relevant discipline, pharmacy, medicine, dentistry, veterinary medicine, pharmacology, chemistry, biology, pharmacy technician, laboratory technician, pharmaceutical regulatory affairs, supply chain management, or security, or a foreign equivalent with an equivalency assessment, and demonstrate sufficient knowledge and experience to carry out the role.

For many smaller dealers and emerging biotech or pharmaceutical companies, identifying a fully qualified QPIC who will assume legal accountability is one of the most underestimated parts of CSR readiness.

Licence Validity and Scope

A CSR dealer's licence specifies the licensed activities and the controlled substances covered, the site municipal address, the security level (determined in accordance with Health Canada's Security Directive), an expiry date of up to a maximum of three years, and any terms and conditions, including production quantities and time periods. Licences are tied to a single site, so multi-site operators hold multiple licences with site-specific terms, security determinations, and personnel.

Ministerial Powers: Partial Suspension

One quiet but consequential change: the Minister of Health can now partially suspend a dealer's licence, narrowing it to specific activities or specific substances rather than only fully suspending or revoking it. This gives Health Canada a more proportionate enforcement tool. From the licensee's perspective, it means a single non-compliance in one corner of operations can be carved out and shut down without halting the entire business. Incident response, CAPA, and documentation discipline matter more than ever.

Hospitals, Government Laboratories, Pharmacists, and Individuals

The CSR is not just about dealers. It reshapes obligations across the ecosystem.

Hospitals gain a clearer framework through the new definition of person in charge of a hospital, an individual responsible for managing all of a hospital's controlled substances activities. Hospitals can sell or provide controlled substances to practitioners for emergency purposes, to licensed dealers, or to the Minister, and may destroy controlled substances on site or send them to a licensed dealer that specializes in destruction.

Government laboratories receive a new authorization to produce, sell, provide, send, deliver, transport, import, or export controlled substances without a dealer's licence, though import and export permits remain required. This exemption applies only to government-operated laboratories, not to private or contract research laboratories.

Pharmacists and pharmacy technicians are governed under a dedicated part of the CSR, with provisions covering compounding, prescription transfers, and prescription extensions consolidated into one place.

Individuals gain a longer 90-day personal-use window for importing or exporting controlled substances other than restricted drugs, an expansion from the 30-day limit that historically applied. Individuals can also now lawfully deliver a prescription drug containing a controlled substance to a patient and bring a controlled substance to a retail pharmacy for destruction.

Cannabis Regulations Harmonization (SOR/2025-244)

The CSR does not stand alone. Companion regulation SOR/2025-244 amended the Cannabis Regulations to align with the CSR, also in force on 1 October 2026. We cover it in detail in our guide to every SOR/2025-244 cannabis change. Notable amendments include:

• Revised master grower responsibilities;
• Allowances for pharmacists to distribute drugs containing cannabis for destruction to licensed dealers and to other pharmacists for prescription fulfilment;
• A new requirement for cannabis licence holders and licensed dealers to record the drug identification number (DIN) for prescription drugs containing cannabis when conducting activities such as import, sale, and distribution.

If your business holds both a cannabis licence and a controlled substances dealer's licence, or operates at the intersection, for example cannabis-derived prescription products, you need to read SOR/2025-242 and SOR/2025-244 together, not separately.

What To Do Now That the CSR Is In Force

If you prepared ahead of 1 October, now is the time to prove the program works in practice. If you did not, the priority is to close the highest-risk gaps fast and document the catch-up. The CSR was one of many changes that landed this autumn, so see our 1 October 2026 compliance countdown for the full picture. The steps below still apply, reframed for a live regulation.

1. Gap analysis against the CSR. Map every SOP, record, system, and personnel role to the corresponding CSR requirement. Identify where current practice falls short, where it exceeds, and where the rule has fundamentally changed, for example the reporting cadence.

2. Confirm your designations. Confirm, in writing, your Senior Person in Charge and Qualified Person in Charge. Verify QPIC credentials against the CSR qualification list. Do not assume a prior designation carries forward.

3. Run your monthly reporting workflow for real. You should already be operating the monthly close: data sources, reconciliation cadence, internal sign-off, escalation paths, and submission method. If a shadow close surfaced gaps, fix them before the next cycle. Strong, inspection-ready SOPs underpin all of it.

4. Re-confirm security. Check your site security against the Security Directive. The CSR ties licence issuance and renewal to security compliance.

5. Finish the SOP refresh and training. Ensure the affected SOPs, recordkeeping, loss and theft reporting, destruction, transportation, import and export declarations, suspicious transaction reporting, reflect the CSR, and that affected personnel are trained with the training documented.

6. Keep records retrievable. Confirm records can be produced on inspection within required timelines.

7. Run a mock inspection. Conduct an internal or third-party mock Health Canada inspection against CSR standards, and close findings through a CAPA process that survives scrutiny.

8. Hold the line month over month. The first few monthly cycles set the pattern inspectors will see. A short inspection-readiness self-assessment each quarter keeps the program honest.

Common Pitfalls and How to Avoid Them

In two decades of regulatory consulting across pharmaceuticals, cannabis, natural health products, and controlled substances, certain compliance pitfalls repeat. The CSR transition is no different. Watch for:

• Treating consolidation as simplification. It is not. Consolidation removes inconsistency, but the underlying rigour is preserved or tightened.
• Underestimating the monthly reporting build. A monthly close needs people, systems, and governance that do not materialize overnight.
• Assuming current QPIC designations carry forward unchanged. The CSR qualification framework is explicit. Verify.
• Letting security drift. Security level determinations under the Security Directive are examined as part of licensing and renewal.
• Ignoring the cannabis interaction. If you handle prescription drugs containing cannabis, your DIN recordkeeping must be airtight.
• Failing to document the transition itself. A clean paper trail of how you analyzed the CSR, the decisions made, and the changes implemented is one of the strongest defences in an early-period inspection.

Frequently Asked Questions

What is SOR/2025-242?

SOR/2025-242 is the Controlled Substances Regulations, a federal regulation made under the Controlled Drugs and Substances Act that consolidates Canada's framework for narcotics, controlled drugs, targeted substances, and restricted drugs into a single rulebook. It came into force on 1 October 2026.

When did SOR/2025-242 come into force?

1 October 2026. Until that date, the former regulations, the Narcotic Control Regulations, the Benzodiazepines and Other Targeted Substances Regulations, and Parts G and J of the Food and Drug Regulations, applied. They are now replaced by the CSR.

Did my existing dealer's licence transfer automatically?

Confirm the specific transitional treatment of your licence against Health Canada guidance and any notices issued around 1 October 2026, rather than assuming it carried over unchanged. MFLRC monitors this guidance and confirms it case by case.

What does monthly reporting require?

Licensed dealers must submit monthly reports on regulated activities, production, packaging, sales, imports, exports, and similar, instead of the former annual cycle. Loss and theft reporting remain separate, with their own 72-hour and 24-hour timelines.

Do I need to re-qualify my Qualified Person in Charge?

Almost certainly, at minimum to confirm that current designations meet the explicit CSR qualification framework. Existing QPICs from former regulations should be re-mapped against the CSR credential and experience requirements.

What happens if I am not compliant now?

Non-compliance with controlled substances regulations carries serious consequences under the CDSA, including suspension, revocation, and prosecution. The Minister also has partial suspension powers under the CSR. Close your highest-risk gaps now and document the catch-up.

Does the CSR change anything for cannabis operators?

Yes. SOR/2025-244 amended the Cannabis Regulations in parallel to harmonize with the CSR, including changes to master grower responsibilities and recordkeeping for prescription drugs containing cannabis.

How MFLRC Guides Clients Through the CSR

This is exactly the kind of regulatory inflection point MFLRC was built for. Twenty-plus years of senior-led practice across pharmaceuticals, cannabis, controlled drugs, and adjacent sectors means we have walked clients through every comparable transition in the last two decades.

Our Regulatory Affairs, Licensing and Import/Export practice handles the strategic side: licence pathway analysis, application drafting, terms and conditions, transitional approvals, and ongoing notifications.

Our Quality Assurance Services team builds and refreshes the QMS architecture CSR compliance needs: SOPs, record systems, designated person frameworks, batch and lot controls, and the documentation discipline inspectors expect.

Our Audit Services practice runs gap analyses, mock inspections, and CAPA programs that turn a regulatory transition into a measurable readiness curve.

And our Pharmaceutical Validation Services function supports the data integrity, computerized system validation, and analytical method work that monthly reporting at scale requires.

Every engagement is led by a senior regulatory consultant with direct Health Canada experience. We do not sell checklists. We build defensible compliance.

Operating Under the CSR? Confirm You Are Compliant Now

The CSR is live. The companies that come through this transition cleanly are the ones treating consolidation as a serious overhaul rather than a paperwork swap, and building defensible compliance from the documentation up.

If you handle controlled substances in Canada, as a manufacturer, dealer, distributor, hospital, laboratory, or pharmaceutical company, book a CSR transition review and confirm your site, SOPs, and reporting meet the new framework.

Navigate regulatory complexity with confidence.

Sources and Further Reading

• Controlled Substances Regulations: SOR/2025-242 - Canada Gazette, Part II, Vol. 159, No. 26
• Regulations Amending the Cannabis Regulations (Harmonization): SOR/2025-244
• Justice Laws Website - SOR/2025-242 Full Text
• Controlled Drugs and Substances Act
• Health Canada - Controlled substances and precursor chemicals